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Antisense therapyMucopolysaccharidosis II is a lysosomal storage disorder caused by mutations in the IDS gene, including exonic
alterations associated with aberrant splicing. In the present work, cell-based splicing assays were performed to
study the effects of two splicingmutations in exon3 of IDS, i.e., c.241CNT and c.257CNT,whose presence activates
a cryptic splice site in exon 3 and one in exon 8, i.e., c.1122CNT that despite being a synonymous mutation is re-
sponsible for the creation of a new splice site in exon 8 leading to a transcript shorter than usual. Mutant
minigene analysis and overexpression assays revealed that SRSF2 and hnRNP E1 might be involved in the use
and repression of the constitutive 3′ splice site of exon3 respectively. For the c.1122CNT theuse of antisense ther-
apy to correct the splicing defect was explored, but transfection of patient ﬁbroblasts with antisensemorpholino
oligonucleotides (n= 3) and a locked nucleic acid failed to abolish the abnormal transcript; indeed, it resulted in
the appearance of yet another aberrant splicing product. Interestingly, the oligonucleotides transfection in con-
trol ﬁbroblasts led to the appearance of the aberrant transcript observed in patients' cells after treatment,
which shows that the oligonucleotides are masking an important cis-acting element for 5′ splice site regulation
of exon 8. These results highlight the importance of functional studies for understanding the pathogenic conse-
quences of mis-splicing and highlight the difﬁculty in developing antisense therapies involving gene regions
under complex splicing regulation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Mucopolysaccharidosis type II (MPS II, Hunter syndrome, OMIM#
309900) is an X-linked, recessive, lysosomal storage disorder (LSD)
caused by mutations in the IDS gene (OMIM* 300823). IDS codes forgonucleotide; AO, antisense
enhancer; ESS, exonic splicing
rotein; ISE, intronic splicing
eic acid; LSD, lysosomal storage






de.pt (S. Alves).the enzyme iduronate-2-sulfatase (IDS, EC 3.1.6.13), which is required
for the degradation of the glycosaminoglycans dermatan and heparan
sulfate. The progressive abnormal storage of these compounds within
the lysosomes leads to the eventual malfunction of different organs
and systems [1]. Although two clinical forms, mild and severe, are
generally recognized inMPS II, they are just the ends of awide spectrum
of clinical severity, likely related to the diversity of mutations affecting
the IDS gene [1].
IDS is located on chromosome Xq28 and spans nine exons [2]. About
20 kb telomeric to the functional gene lies a functional pseudogene
showing homology with exons 2 and 3 and introns 2, 3 and 7 [3-5].
More than 500 MPS II causal mutations have been reported in IDS, of
which around 9% are single nucleotide substitutions that affect splice
site signals (www.hgmd.org; [6]). However, this ﬁgure is probably an
underestimate since the direct analysis of mRNA is not routinely per-
formed in the diagnostic setting. Thus, the impact ofmissense, nonsense
and synonymous mutations involved in the downregulation of splicing
2713L. Matos et al. / Biochimica et Biophysica Acta 1852 (2015) 2712–2721mechanismsmay remain unknown; this is especially plausible for genes
with a ﬁne balance between constitutive and cryptic splice sites such as
IDS, which requires the interaction of several auxiliary cis-acting ele-
ments for proper splicing to occur [7-9].
Splicing mutations can interfere with accurate pre-mRNA splicing if
they affect nucleotides at (or in the vicinity of) acceptor (AG) or donor
(GT) splice sites (detectable at the genomic DNA level). Correct consen-
sus sequence recognition also relies on so-called exonic and intronic
splicing enhancers (ESE and ISE) or silencers (ESS and ISS). These are
usually bound by arginine–serine (SR) proteins and heterogeneous
nuclear ribonucleoproteins (hnRNP) respectively. Regardless of their
type (nonsense, missense or synonymous), single nucleotidemutations
can interfere with all these internal splicing regulatory elements,
causing partial or total exon skipping, intron retention, the creation of
ectopic splice sites, and the activation of cryptic sites [7,10,11]. None
of these effects can be deduced from the analysis of genomic DNA.
The understanding of basic splicingmechanisms is important if ther-
apeutic strategies that might correct splicing defects are to be designed.
Several studies have explored the potential of targeting aberrant pre-
mRNA resulting from splicing mutations. These include the use of
smallmolecule compounds thatmodulate alternative splicing, the over-
expression or silencing of splice factors, trans-splicing approaches
(spliceosome-mediated RNA trans-splicing, SMaRT), use of adapted U1
snRNAs complementary to the mutated site and antisense oligonucleo-
tides used to correct mutation-induced aberrant splicing (Splice-
switching oligonucleotides) or to redirect splicing to knock-down
gene expression [12,13]. One of the most promising genetic therapies
of this kind is pre-mRNA targeting by antisense oligonucleotides
(AOs). These have been used to mask abnormal or cryptic splice sites
and regulatory regions away from the mutated site aiming to restore
pre-mRNA processing. AOs hybridize to a selected site in the pre-
mRNA, and thus sterically hinder the recognition of a speciﬁc region
by the spliceosomal machinery. The usage of the natural splice
site(s) is thus promoted, recovering the production of normally spliced
transcripts [14,15].
The modiﬁcation of splicing by AOs has been shown effective in
β-thalassemia (HBB gene) [16], ataxia-telangiectasia (ATM gene)
[17,18], pyridoxine-dependent epilepsy (ALDH7A1 gene) [19],
hypomyelinating leukodystrophy (PLP1 gene) [20], Niemann–Pick
disease (NPC1 gene) [21] and organic acidemias (PCCA, PCCB and MUT
genes) [22,23]. AOs have also been used to modify alternative splicing
in spinal muscular atrophy (SMN2 gene) [24], and to target the pre-
mRNA of genes involved in cancer such as Bcl-x [25] and C-myc [26,
27]. Phenotypic improvements have been achieved using AOs in vitro
and in animal models of Duchenne muscular dystrophy for which anti-
sense therapy is now in the early phases of clinical trials [14,28].
In a previous study [29] involving Portuguese patients with MPS
II, we detected several splicing mutations, some of which gave rise
to alternative transcripts. Some involved exon 3 of IDS; the pre-
mRNA region of this exon is particularly vulnerable to defects in
splicing regulation. In the present work, functional analysis based
on reporter minigenes was performed for two exon 3 nucleotide
changes, c.257CNT [29-31] and c.241CNT [32], which conﬁrmed
these to be involved in exon 3 splicing dysregulation. Further, mu-
tant minigene analysis and overexpression assays revealed that the
SRSF2 (formerly SC35) and hnRNP E1 proteins might be involved in
the use and repression of the constitutive 3′ splice site of exon 3
respectively.
Although enzyme replacement therapy is already available for MPS
II, it has some serious limitations, justifying, therefore, the development
of novel therapies for this disease. Hence, for MPS II patients' affected
by splicing mutations, splicing therapeutics is a potential alternative or
an adjunct therapeutic strategy. With this aim, tests were also per-
formed to see whether AOs could be used to circumvent the effect of
c.1122CNT [29,33], an exonic nucleotide change that creates a new 5′
splice site inside exon 8. The transfection of three antisensemorpholinooligonucleotides (AMOs) and one locked nucleic acid (LNA) in patient
ﬁbroblasts did not abolish the abnormal transcript.
2. Material and methods
2.1. Patients and healthy individuals
Fibroblasts were obtained (during routine genetic analysis and
under informed consent) from three male Portuguese patients - all
carriers of one knownmutation (Table 1) -with a biochemical diagnosis
of MPS II, and from anonymous healthy donors. The conﬁdentiality of
personal data was respected at all times.
2.2. Cell culture and cycloheximide treatment of patients' ﬁbroblasts
Fibroblasts, used as a source of mRNA and genomic DNA, were
cultured following standard procedures in DMEM medium (Gibco
Invitrogen, Carlsbad, USA) with 10% FBS and 1% kanamycin at 37 °C in
a 5% CO2 atmosphere.
To perform the nonsense-mediated mRNA decay (NMD) assays,
ﬁbroblast cells from Patient 1 (c.241CNT) and 2 (c.257CNT) were cul-
tured in the presence of three different concentrations of cycloheximide
(0.75, 1 and 2 mg/ml) for 6 h. Total RNAwas then isolated and reverse-
transcribed as described above. RT-PCR was performed using speciﬁc
primers for exons 2 and 3 (Table I in [34]).
2.3. Molecular investigation
For molecular genetic analysis, genomic DNA was extracted
automatically using a Bio Robot EZ1® system and the EZ1 DNA Tissue
Extraction Kit (Qiagen, Hilden, Germany), following the manufacturer's
instructions. Speciﬁc primers were used to amplify DNA fragments con-
taining the nine exons of the IDS gene and their intronic ﬂanking regions
[29]. Total mRNA was isolated using the High Pure RNA Isolation Kit
(Roche Applied Science, Indianapolis, USA) and reverse-transcribed
using the “Ready-To-Go You-Prime First-Strand Beads” Kit (GE
Healthcare, Buckinghamshire, UK), following the manufacturer's
protocol. For RT-PCR, the speciﬁc primers shown in Table I [34]were de-
signed using the Ensembl database (www.ensembl.org; Transcript: IDS-
001 ENST00000340855). cDNA ampliﬁcations were performed in a
total volume of 25 μl using the Hot-Start PCR Mastermix Immomix
Red Kit (Bioline, London, UK), following the manufacturer's instruc-
tions, employing 0.2 μM of each primer and an annealing temperature
of 60 °C (35 cycles). All PCR products were puriﬁed directly with Illustra
ExoStar 1-Step™ (GE Healthcare, Buckinghamshire, UK), or after gel ex-
traction using theWizard® SV Gel and PCR Clean-Up System (Promega,
Madison, USA). Sequencing reactions were then performed in an ABI
Prism 3130xl genetic analyzer (Applied Biosystems, Foster City, USA).
Sequencing proﬁles were compared with the IDS reference sequence
ENSG00000010404 (www.ensembl.org) using the ClustalW2 bioinfor-
matic tool (www.ebi.ac.uk/Tools/msa/clustalw2/).
2.4. Mutation nomenclature
The sequence used as reference for numbering the residues was the
Ensembl sequence ENSG00000010404, and themutation nomenclature
was done in accordance with the recommendations of the Human
Genome Variation Society (www.hgvs.org/mutnomen/).
2.5. Bioinformatic analysis
Prediction of the splicing scores for the natural, cryptic donor and
acceptor splice sites was obtained using the MaxEntScan software:
Maximum Entropy Model with idealMaxEnt splice site scores of 11.81
for 5′ splice site and 13.59 for 3′ splice site (http://genes.mit.edu/
burgelab/maxent/Xmaxentscan_scoreseq.html) [35]. Modeling of the
Table 1






Mutation type In silico effect of gDNA changeb Reference
1 c.241CNT p.Q81X (CAA-TAA) Nonsense/splicing Reduction in splicing score for 3′ splice site (8.78 to 8.13) Brusius-Facchin et al. [32] and present study
2 c.257CNT p.P86L (CCG-CTG) Missense/splicing
Creates an SRSF1 binding site and eliminates the hnRNP E1,
hnRNP E2 and SRSF2 binding sites
Bunge et al. [30], Flomen et al. [31] and Alves
et al. [29]
3 c.1122CNT p.G374G (GGC-GGT)
Synonymous/
splicing
Increase in splicing score for 5′ splice site (7.46 to 9.22) Popowska et al. [33] and Alves et al. [29]
a The mutation nomenclature is that recommended by HGVS. cDNA and protein numbering is based on the reference sequence in Ensembl (Ensembl sequence ENSG00000010404),
taking nucleotide +1 as the A of the ATG translation initiation.
b In silico effect analyzed by Splicing Rainbow and ESEﬁnder 3.0 software.
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performed using ESEﬁnder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/
ESE3/eseﬁnder.cgi?process=home) [36,37] and Splicing Rainbow
(http://www.ebi.ac.uk/asd) [38] software.
2.6. Minigene construction
For the in vitro splicing analysis of the variants c.241CNT and
c.257CNT in IDS exon 3, the respective regions of patient and healthy
control genomicDNAwere ampliﬁed. Since an IDSpseudogene [3-5] ex-
ists that shows high homology with the IDS gene in the region corre-
sponding to exons 2, 3 and introns 2 and 3, primers for these
ampliﬁcations were designed to anneal at intron 1 and 3 in such a
way that the ampliﬁed fragment matched the corresponding gene and
not the pseudogene. A BamHI (Forward primer – Intron 1 BamHI
F) andXhoI (Reverse primer - Intron 3XhoI R) restriction enzyme cleav-
age site tail was added to each oligonucleotide (Table I in [34]). The PCR
conditions were as described above. The fresh products were then
subcloned into the TOPO vector (Invitrogen, Carlsbad, USA) followingFig. 1. Agarose gel showing the IDS transcripts observed in the three MPS II patients together
structure of each ampliﬁed fragment. The diagrams show the position of the three splicing mut
are shown in colored boxes above the corresponding 5′ and 3′ splice sites. A)Negative control (N
PCR showed one band for the control ﬁbroblasts and two for those of Patients 1 and 2. In both pa
c.241CNT (P1) and c.257CNT (P2) in exon 3. The lower band reveals the deletion of the ﬁrst 44
ampliﬁcation of patient mRNA between exons 7 and 9 revealed an aberrant transcript lackingthe manufacturer's protocol. The inserts were cut with BamHI and
XhoI, and puriﬁed after gel excision. Using the Rapid Ligation Kit
(Roche Applied Science, Indianapolis, USA) they were also cloned into
pcDNA3.1-myc, a modiﬁed plasmid vector (Invitrogen, Carlsbad, USA)
that contains the sequence for the Myc epitope (to be used as a se-
quence tag) upstream of the multiple cloning site (Fig. 1A in [34]).
To validate the in silico predicted changes in the splicing factors
SRSF2 (formerly SC35), hnRNP E1 and hnRNP E2 (also known as α-
CP1 or PCBP1 and α-CP2 or PCBP2) in the presence of the c.257CNT
mutation, a mutant minigene was designed containing a small deletion
(GCCCCGAGCC) in the mutated region which comprises the predicted
cis-actingmotifs for the binding of bothmentioned trans-acting factors.
Thewild-type (WT) exon 3minigenewas used as template and themu-
tated minigene (ex3 del ESE/ESS motifs) was ordered from Nzytech
(Lisbon, Portugal).
To functionally investigate the splicing defects caused by c.1122CNT
in exon 8, wild-type and mutant minigenes were constructed in vector
pSPL3 (Exon Trapping System, Life Technologies, Gibco, NY, USA), a
speciﬁc vector for splicing analysis in which the multiple cloning sitewith schematic views of each transcript's constitution. Sequencing analysis identiﬁed the
ations and its effects on splicing. The splicing scores calculated usingMaxEntScan software
C); healthy control (C) and Patients 1 (P1) and 2 (P2). Agarose gel electrophoresis after RT-
tients the upper band revealed a sequencewith exons 2 and 3,with the nucleotide changes
bp of exon 3 in both patients. B) Negative and healthy control, and Patient 3 (P3). RT-PCR
the last 60 bp of exon 8.
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fragments comprising exon 8 and its intronic ﬂanking regions were
ampliﬁed from the DNA of both control and patient ﬁbroblasts using
the primers shown in Table I [34], employing the PCR conditions
described above. After subcloning into the TOPO vector, each insert
was excised with EcoRI, puriﬁed, and cloned into the pSPL3 ﬁnal vector
(Fig. 1C in [34]). All clones were veriﬁed by DNA sequencing.
2.7. In vitro splicing assays
The in vitro splicing assays were performed in COS-7 and Hep3B cell
lines to investigate which one best reproduces the endogenous splicing
pattern observed in patients. For that, cells from both lines (4 × 105)
were grown in 6-well plates and transfected with WT or mutant
minigenes (2 μg) using 4 μl of Lipofectamine 2000 (Invitrogen, Carlsbad,
USA) according to the manufacturer's instructions (performed in tripli-
cate). Following the same conditions themutantminigene (ex3 del ESE/
ESS motifs) was transfected in Hep3B cells. At 24 h post-transfection,
total RNA was extracted from the cells and used as a template for
cDNA synthesis. RT-PCR was then performed as described above,
using vector speciﬁc pcDNA3.1-myc (K-myc-Bam and pfGHr1) or
pSPL3 (SD6 and SA2) primers (Table I in [34]). The ampliﬁed products
were separated by agarose gel electrophoresis. Following band excision
and puriﬁcation they were subjected to direct sequencing using an ABI
Prism 3130xl genetic analyzer (Applied Biosystems, Foster City, USA).
2.8. Overexpression and depletion of splicing factors
To conﬁrm the predicted changes in the splicing factors SRSF2,
hnRNP E1 and hnRNP E2, overexpression and depletion studies
were performed using plasmids coding for them (kindly provided by
Dr. B. Andersen and Dr. S. Liebhaber) and siRNAmolecules respectively.
Some 4 × 105 Hep3B cells grown in 6-well plates were co-transfected
with plasmids encoding the SRSF2, hnRNP E1 or E2 trans-acting factors
(using 1.5–3.5 μg of each minigene), plus 2 μg of WT or mutant
minigenes. All transfections were performed using Lipofectamine
2000 reagent. The amount of plasmid DNA was adjusted as necessary
using empty vector (i.e., without any insert). At 48 h post-
cotransfection, the cells were harvested and the transcript pattern
analyzed by RT-PCR as described above.
Depletion studieswere also performed in theHep3B cell line. Cells at
30–40% conﬂuence were transfected (using Lipofectamine 2000) with
siRNA (200 μM) targeting the mRNA of SRSF1 (formerly ASF/SF2) and
luciferase (control). These cells were then transfected with the WT or
mutantminigene (c.257CNT) 24 h later. RT-PCR analysiswas performed
48 h later. All siRNA oligos came from MWG Biotech (Ebersberg,
Germany); the sequences are described in Table I [34].
The overexpression of SRSF2 and hnRNP E1 and hnRNP E2 was con-
ﬁrmed in whole cell lysates by quantitative Real-Time PCR (qRT-PCR).
Brieﬂy, 1.5 μg of total RNA was reverse-transcribed using NOT I-d(T)18
bifunctional primer with ﬁrst-strand mix beads from the Ready-To-Go
You-Prime First-Strand Beads Kit (GE Healthcare, Buckinghamshire,
UK) according to the manufacturer's protocol. Relative levels of gene
expression were analyzed using TaqMan Universal PCR Master
Mix 1× (Applied Biosystems) and the TaqMan Gene Expression Kit
(which includes primers and probes for each speciﬁc splicing factor
gene –Table I in [34]), following the recommended PCR conditions.
The relative mRNA levels of target genes were calculated using
standard curves (values ranging from0.05 ng to 50 ng of RNA converted
into cDNA). A standard curve was constructed for each target gene
relating Ct values (the fractional cycle number at which the amount of
ampliﬁed target reached a ﬁxed threshold) to log RNA quantities. The
normalization of expression was given by the ratio between the RNA
concentrations of each target gene and the endogenous gene PGK1.
The relative amount of RNAwas determined via the ratio of the normal-
ized expressions of the target and control samples.Depletion of SRSF1 was conﬁrmed in whole cell lysates through a
qRT-PCR assay as described above and also by Western blotting. For
protein analysis, samples were boiled for 10 min and resolved in a
12% SDS-PAGE mini-gel. After electrophoresis, proteins were trans-
ferred to a polyvinylidene diﬂuoride membrane using a Mini Trans-
Blot cell (Bio-Rad). Immunodetectionwas carried out using the primary
antibodies mouse anti-SF2/ASF clone 96 from Zymed (San Francisco,
CA) and anti-α-tubulin from Sigma-Aldrich (Switzerland).
2.9. Antisense oligonucleotide treatment and analysis
AMOs were designed to target the new 5′ splice site created in the
presence of themutation c.1122CNT in exon 8. AMOswere synthesized
and puriﬁed by Gene Tools (Philomath, OR). A standard 25-mer
morpholino control oligonucleotide (also provided by Gene Tools)
was used as a negative control (Table I in [34]). Endo-Porter Reagent
(Gene Tools) was used as the peptide delivery system, following the
manufacturer's recommendations. For the AMO treatment, between 3
and 4 × 105 ﬁbroblasts from control and patient were grown in 6-well
plates and after overnight culture different concentrations of each
AMO were added with 9 μl/ml of Endo-Porter. The scrape delivery
method was also used to help cells incorporate AMOs [39].
To target and block the new 5′ splice site in exon 8, an LNA was
designed and synthesized by Exiqon (Vedbaek, Denmark) (Table I in
[34]). For LNA exposure, ﬁbroblasts from control and patient were
plated under the same conditions as described for AMO treatment.
After overnight incubation, different concentrations of LNA were
added to cells using Lipofectamine LTX or 2000 (Invitrogen, Carlsbad,
USA) as delivery reagents.
After 24 h and 48 h treatmentwith the different AMOs and LNA, cells
were harvested, total mRNA isolated, and RT-PCR performed as
described above using the forward and reverse primers for exon 7 and
9 respectively (Table I in [34]).
3. Results
3.1. Genetic analysis of patient-derived ﬁbroblasts
Table 1 shows the genetic defects carried by the patients. Patient 1
was hemizygous for a nucleotide change in exon 3, c.241CNT
(p.Q81X) already erroneously reported as p.Q80R by Brusius-Facchin
et al. [32]. A detailed analysis of the codon in the HGMD database (Pro-
fessional 2014.3 Release) showed the mutation reported by these au-
thors was, in fact, Q81X. The impact of this change at the RNA level
and its effects on IDS pre-mRNA splicing is here addressed for the ﬁrst
time.
Transcriptional analysis of IDS cDNA from Patient 1 revealed two
transcripts, one corresponding to a normal splicing product with the
CNT change in the ﬁrst nucleotide of exon 3 (predicted to introduce
an early stop codon at position 81 [p.Q81X]), and the other correspond-
ing to an aberrant transcript lacking the ﬁrst 44 bp of exon 3 (predicted
to code for a truncated protein with only 83 amino acids) (Fig. 1A). This
additional transcript suggests that this point mutation interferes with
splicing. Further, since both transcripts bear a premature STOP codon,
they are likely targets for nonsense-mediated mRNA decay (NMD),
with no protein being produced. When patients' cells were treated
with cycloheximide, an inhibitor of the NMD mechanism, a clear in-
crease in the intensity of the band which corresponds to the transcript
bearing the nonsense mutation Q81X (Fig. 2) was observed, meaning
that this transcript is targeted byNMD. Regarding the abnormal splicing
product (with the absence of 44 bp), despite being a potential target for
NMD (once leads to a truncated protein, p.Q81EfsX2), no signiﬁcant
changes were observed in the intensity of the corresponding band.
The classical NMD pathway is thought to be trigged during the pioneer
round of translation when the ﬁrst ribosome translates the processed
mRNA and stalls at a PTC that is located more than 50–55 nucleotides
Fig. 2. Cycloheximide treatment. RT-PCR ampliﬁcation of RNA extracted from
mucopolysaccharidosis II patients with the nonsense c.241CNT (P1) and missense
c.257CNT (P2) mutations untreated (0 mg/ml) or treated with cycloheximide (1.0 mg/ml)
for 6 h. The same results were obtained with 0.75 and 2.0 mg/ml (data not shown). The
ampliﬁcation of awild-type sample (C) is also presented. NC—negative control; C— control;
P— patient; CHX— cycloheximide.
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is growing evidence that mutation, codon, gene, cell and tissue-speciﬁc
differences in NMD efﬁciency can alter the underlying disease patholo-
gy. Moreover, inter-individual variation in NMD efﬁciency among pa-
tients carrying identical mutations have also been reported [41,42].
The differences in the NMD mechanism activation here observed be-
tween two transcripts having PTCs could be explained by this recent
data.
cDNA analysis was performed for ﬁbroblasts from Patients 2 and 3,
who carried mutations already described and previously analyzed in
our group [29]. The transcript pattern for Patient 2, who carried the
nucleotide change c.257CNT in exon 3, was similar to that observed
for Patient 1 (Fig. 1A). Cycloheximide experiments were also performed
in this case and, as described for Patient 1, no signiﬁcant changes in the
intensity of the band corresponding to the transcript lacking the 44 bp
were observed (Fig. 2). The nucleotide change c.1122CNT carried by
Patient 3 (Fig. 1B) was expected to be synonymous in terms of amino
acid coding [p.G374G (GGC-GGT)], but the cDNA analysis revealed the
presence of a transcript lacking the last 60 bp of exon 8. As previously
described [29,30], the normal transcript was also present but in lower
quantities. The presence of this transcript even in lower quantities is
responsible for the mild phenotype of this patient. In our previous
study [29] we have determined patients' enzymatic activities and for
this patient we have observed a relatively higher IDS enzymatic activity,
in comparison with other MPS II cases.
3.2. Bioinformatic analysis
Splicing scores for the splice site junctions were found compatible
with the splicing changes observed in cDNA. For the mutation
c.241CNT, in silico analysis predicted a reduction in the 3′ splice site
score value from 8.78 to 8.13. Under these circumstances the constitu-
tive splice site continued to be used, but the regulation of splicing in
this region was perturbed and a downstream cryptic splice site (8.89)
was also used, producing a second transcript without the ﬁrst 44 bp of
exon 3 (Fig. 1A). In contrast to what we have observed before [29] for
two other IDS mutations (c.241−2ANG and c.241−1GNA) which
affect the same splice site, in the case of the c.241CNT change the
presence of a transcript with the total skipping of the exon 3 was not
detected. In fact, the two other mutations affect the 3′ invariable splice
site sequence, being responsible for a drastic reduction of the splice
site score. That is not the case of c.214CNT change, once this mutation
alters the ﬁrst base of the exon 3, causing only a slightly decrease in
the 3′ splice site score (from 8.78 to 8.13) which might explain the
aberrant splicing pattern differences observed.
For the c.257CNT mutation, in silico analysis returned a higher splic-
ing score for the 3′ cryptic splice site in exon 3 (8.89) than for its consti-
tutive counterpart (8.78) (Fig. 1A).The change in c.1122CNT was shown to be associated with the acti-
vation of a new 5′ splice site in exon 8, which returned a higher splicing
score (9.22) than the original splice site (7.46) (Fig. 1B).
Since theMaxEntScan-estimated splicing scores did not completely
account for the perturbation in constitutive splicing, further bioinfor-
matic toolswere used to search for differences in exonic splicing regula-
tory elements between the WT and mutated sequences of exon 3. For
the nucleotide change c.241CNT, neither the Splicing Rainbow [38] nor
the ESEﬁnder 3.0 [36,37] software's predicted alterations in any exonic
splicing regulatory element. In the presence of the c.257CNT nucleotide
change, analysis with Splicing Rainbow software predicted the elimina-
tion of a binding motif for the hnRNP E1 and hnRNP E2 silencing pro-
teins, and the creation of an SRSF1 (formerly ASF/SF2) recognition
motif (Fig. 2A in [34]). Analysis with ESEﬁnder 3.0 software indicated
the recognition motif for SRSF1 would be slightly altered, and that a
binding site for SRSF2 (formerly SC35) would no longer be recognized
in the presence of the mutation (Fig. 2B in [34]).
3.3. Functional analysis of IDS gene splicing mutations
To further study the effect of the three exonic changes on splicing
patterns, minigene assays were performed using constructs generated
with WT or mutant exons (plus their respective intronic ﬂanking
regions) in the pcDNA3.1-myc or pSPL3 vectors (Fig. 1A and C in [34]).
Fig. 1B and 1D [34] shows the results of RT-PCR splicing analysis after
the transfection of COS-7 and Hep3B cells: the ampliﬁed transcripts
derived from the WT and mutant minigenes are shown in 1B) for the
nucleotide changes in exon 3, and in 1D) for the mutation in exon 8.
The transcript patterns for the three IDSmutations were similar in
both the Hep3B and COS-7 cells, although slight qualitative differences
in expression were detected in the minigene assays.
3.4. Splicing regulatory elements analysis
To validate the predictions for the trans-acting factor proteins in-
volved in the 3′ splice site choice of IDS exon 3, they were either
overexpressed or silenced in Hep3B cells transfected with either WT
or mutant minigenes constructed for c.257CNT. cDNA analysis after
overexpression of the SRSF2 protein in Hep3B cells with the mutant
c.257CNT minigene revealed the rescue of the normal transcript and
the disappearance of the aberrant form lacking the ﬁrst 44 nucleotides
of exon 3 (Fig. 3B). This strongly suggests that the choice of the 3′ con-
stitutive splice site of IDS exon 3 may be dependent on an ESE site
recognized by SRSF2. This recognition is compromised by the mutation
c.257CNT.
The c.257CNTmutationwas further predicted to eliminate a binding
motif for the splicing silencers hnRNP E1 and hnRNP E2. The overex-
pression of hnRNP E1 with the mutant (c.257CNT) minigene resulted
in a substantially increased production of the aberrant transcript, show-
ing that the cryptic splice site activated downstream was preferentially
chosen (Fig. 3C). This suggests the involvement of hnRNP E1 in the
repression of the 3′ constitutive splice site of exon 3. When hnRNP E2
was overexpressedwith themutant (c.257CNT)minigene, no alteration
in the mutant splicing pattern was seen (Fig. 3C). Individual co-
transfection of SRSF2, hnRNP E1 or hnRNP E2 plus the WT minigene
did not modify the WT splicing pattern (Fig. 3A).
Finally, to determine whether the c.257CNT change interfered with
the recognition of the splicing enhancer SRSF1, as bioinformatically
predicted, endogenous protein in the Hep3B cells was depleted through
RNA interference. The cells were then transfected with WT or mutant
minigenes. No changes were detected in the transcriptional proﬁles of
either the WT or mutant sequences (Fig. 3D).
The degree of overexpression or suppression achieved for each
splicing factor was analyzed by qRT-PCR using speciﬁc probes, and by
Western blotting in the case of SRSF1 depletion (see Material and
Methods). The relative quantiﬁcation of each RNA, via the ratio of the
Fig. 3. Analysis of the involvement of speciﬁc SR and hnRNP trans-acting factors in the regulation of the 3′ splice site of exon 3. The results of RT-PCR analysis using vector-speciﬁc primers
are shown alongwith a diagramof the transcripts obtained inHep3B cells after 24 h or 48 h of incubation. A) Co-transfection of thewild-type exon 3minigene (2 μg)with each trans-acting
factor (3.5 μg). B) Overexpression of SRSF2 (formerly SC35) (3.5 μg) after transfection with the c.257CNT mutant minigene (2 μg). C) RT-PCR analysis of processed transcripts after co-
transfection with hnRNP E1 or hnRNP E2 (3.5 μg) plus the mutant minigene c.257CNT (2 μg). D) Splicing pattern of the minigene reporter transcripts following depletion of endogenous
SRSF1 (formerly ASF/SF2) and luciferase (control). For the silencing of both proteins, 200 μMof each siRNAwere used. Note that only the SRSF2 and hnRNP E1 trans-acting proteins had an
effect (respectively) on the constitutive and alternative splicing of IDS exon3. The same resultswere obtainedwhenbetween1.5 μg and3 μg of the trans-acting factorswere overexpressed.
E) Transcript pattern obtained after expression of 2 μg of the exon 3 mutant minigene (ex3 del ESE/ESS motifs) with the deletion of 6 bp (GCCCCGAGCC) of predicted exonic motifs with
overlapping sequences for the binding of SRSF2 and hnRNP E1 and hnRNP E2 proteins. NC — negative control; V — vector sequence; siRNA — small interfering RNA.
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the efﬁcacy of SRSF2, hnRNP E1 and hnRNP E2 overexpression, as well
as SRSF1 depletion (Table II in [34]). SRSF1 depletion was also con-
ﬁrmed by immunodetection (Fig. 3 in [34]).
The expression in Hep3B cells of themutant minigene (ex3 del ESE/
ESS motifs) containing the deletion of 6 bp (GCCCCGAGCC) of the pre-
dicted cis-acting motifs for the binding of SRSF2 and hnRNP E1 and E2
showed the aberrant splicing pattern observed in the presence of the
c.257CNT mutation (Fig. 3E). This result, as the ones obtained with
the overexpression of SRSF2 and hnRNP E1 proteins, points to the
involvement of these two trans-acting factors in the regulation of
the 3′ constitutive splice site of IDS exon 3.
3.5. Antisense oligonucleotide studies in control and patient ﬁbroblasts with
the mutation c.1122CNT in IDS gene: a therapeutic approach
Given that the mutation c.1122CNT in exon 8 has a silent effect on
the amino acid sequence, the possibility of redirecting transcript pro-
cessing using modiﬁed antisense oligonucleotides of two different
types was examined. Three AMOs and one LNA complementary to the
region of the newly created 5′ splice site (Fig. 4A) were designed in an
attempt to block the access of the splicing machinery to the mutant
pre-mRNA, and consequently circumvent the formation of the aberrant-
ly spliced transcript. cDNA analysis was performed 24 h and 48 h after
transfection of the patient and control ﬁbroblasts. In patients' ﬁbro-
blasts, under none of conditions tested (30 or 50 μM of each AMO, and
1, 5, 25, 50 or 100 nM of LNA) was the abnormally spliced mRNA ever
abolished. The RT-PCR results (Fig. 4B and C) also showed a transcript
skipping exon 8 in the presence of the different AOs, alongside theabnormal transcript showing partial skipping of exon 8. In control ﬁbro-
blasts transfected with 50 μMof each AMO, the RT-PCR results revealed
three different transcripts: one of normalmolecular weight, one lacking
the last 60 bp of exon 8 and onewith the total skipping of exon 8. On the
other hand, the transfection of 50 and100 nMof LNA lead to the appear-
ance of one aberrant transcript presenting the total skipping of exon 8
(Fig. 4D).
The AMO treatment proved to be sequence-speciﬁc since an AMO
with a scrambled sequence had no effect on the exon 8 splicing pattern
in patient ﬁbroblasts (data not shown).
4. Discussion
A number of diseases have been linked tomutations that disrupt the
splicing process, which leads to abnormal and/or deﬁcient protein
production [9,43]. Splicing defects represent more than 9% of all
currently published mutations [6], although this ﬁgure might well be
underestimated since our knowledge on the regulatory elements that
inﬂuence splicing in many genes is far from complete. Genomic DNA
and cDNA analyses (including functional studies addressing the effect
of speciﬁc mutations on splicing) are needed if we are to develop
therapeutic strategies for correcting molecular defects. In the present
work, one of themutations causing aberrant splicingwas a synonymous
substitution. This led us to explore the possible use of antisense oligonu-
cleotide therapy for redirecting abnormal pre-mRNA splicing.
Under physiological conditions, the IDS gene is associated with at
least 8 transcripts produced by alternative splicing (Vega Genome
Browser; VEGA: http://vega.sanger.ac.uk/), four of them are protein
coding, two are thought to undergo NMDand the last two are processed
Fig. 4.Antisense oligonucleotide treatment of control and patientﬁbroblasts. A) Illustration of the IDS exon8 regionwhere thenucleotide change c.1122CNT is located (T changemarked in
bold gray). The underlined sequences represent each blocking AMOor LNA. B) RT-PCR analysis ofmRNA fromuntreated control cells (C) and from Patient 3 (P3) ﬁbroblasts (0 μM), aswell
as from P3 cells treated for 24 hwith 50 μMof AMO 1, 2 or 3 targeting the new 5′ splice site. C) Same analysis as in B but performed for P3 cells treated for 24 hwith 50 and 100 nMof the
speciﬁc LNA. D) cDNA analysis of control ﬁbroblasts after treatment with 50 μMof AMOs or 50 and 100 nMof LNA. Samples of untreated control (C) and P3 ﬁbroblasts are also presented.
The same results were obtained after 48 h of treatment with the three AMOs and LNA (data not shown). NC— negative control.
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a complex underlying regulatory mechanism that probably requires the
interaction of multiple splicing factors. This, of course, also renders this
system sensitive to mutations that disrupt splicing. Regulatory
sequence elements act in vivo as binding sites for speciﬁc SR and
hnRNP trans-acting factors that, respectively, promote and inhibit splice
site recognition and spliceosome assembly around a given exon.
hnRNPs can disturb the protein-protein interactions of SR proteins,
and thus compete with them in splice site recognition [11,44].
For the three disease-causing mutations analyzed in the present
work, the in vitro splicing analysis of speciﬁc minigenes closely
reproduced the pattern seen in patient ﬁbroblasts. Therefore, the cis
and trans-acting elements involved in exon 3 splicing regulation were
examined in further studies.
The c.257CNT mutation seemed to abolish the exonic splicing
enhancer (ESE) for the SRSF2 (formerly SC35) protein, which is predict-
ed to be necessary for the constitutive transcription of exon 3 in theWT
context. The overexpression of this SR protein along with the mutant
minigene compensated for the aberrant splicing by favoring the
selection of the constitutive 3′ splice site by the splicing machinery. In
agreement, theMaxEntScan splicing score for the 3′ constitutive splice
site (8.78) was lower than for the cryptic site situated downstream
(8.89). All these ﬁndings are consistent with the documented model
for ESE function, inwhich ESE-bound SRproteins are thought to activate
weak 3′ splice sites by increasing the recruitment of U2AF65/35 and
improving its binding stabilization via protein-protein interactions
between the SR protein and the U2AF35 RS domains [45,46].
The c.257CNTmutationwas further predicted to eliminate a binding
site for the splicing silencers hnRNP E1 and hnRNP E2; this site overlaps
with the interrupted sequence motif for SRSF2 recognition (Fig. 2A
in [34]). Overexpression of the hnRNP E1 factor with the mutant
minigene resulted in the increased expression of the aberrant transcript,
showing that this trans-acting factor, which has been reported as a
splicing regulator [47-49], may indeed inhibit the recognition of the 3′
constitutive splice site, thus favoring abnormal alternative splicing.
Moreover, the transfection of Hep3B cells with a mutant minigene
(ex3 del ESE/ESS motifs) presenting the deletion of a 6 bp sequence
(CCCGAG)which comprises the predicted cis-actingmotifs for the bind-
ing of SRSF2 and hnRNP E1 lead also to the appearance of the aberrant
splicing product with the absence of the 44 bp. This observation further
supports the hypothesis that this region contains important cis-acting
elements for the regulation of the 3′ splice site of exon 3.The in vitro expression or silencing of splicing factors can modulate
splicing patterns, revealing that precise combinations and relative ratios
of factors dictate regulatory decisions [10,50]. Overall, the present re-
sults suggest that the binding of hnRNP E1 to exon 3 can modulate the
interaction of SRSF2 with an overlapping site (Fig. 5). The mutant
minigene analysis together with the overexpression data for both pro-
teins indicate that SRSF2 binding to the ESE seems to be important for
splicing of the upstream intron, and that it might depend on changes
in the concentration ratio between the SR protein and hnRNP E1. Fur-
ther, and notably, the overexpression of hnRNP E1 via theWTminigene
showed no alteration of the normal splicing pattern; thus, an excess of
hnRNP E1 may be insufﬁcient to antagonize the binding of SRSF2 and
disturb constitutive splicing. This suggests that differences in the con-
centrations of these RNA-binding proteins may be required for exon 3
to be silenced by hnRNP E1. A similar occlusion model involving the
hnRNP A1 and SRSF2 protein splicing factors has been described in
which the function of hnRNP in tat exon 2 splicing was to inhibit the
binding of SRSF2 to an overlapping site [51,52]. The ability of hnRNPs
to interfere with the binding of SR proteins has also been described in
other pre-mRNAs [53-55].
hnRNP E1 and hnRNP E2 are highly homologous proteins, with 89%
amino acid similarity [56]. Nonetheless, the overexpression of hnRNP E2
with the WT and mutant constructs did not alter the splicing pattern.
This shows that, despite being very alike, they may recognize different
sequencemotifs. Distinct functions for these proteins have been report-
ed by other authors [49,57].
As a whole, these ﬁndings contribute towards our better under-
standing of the molecular splicing mechanism of IDS. The results, like
others reported for disease-related mutations [58-61], are of
importance for clarifying the basic mechanisms underlying IDS-
associated splicing, but improve our knowledge of the splicing process
in general. This is a prerequisite for the design of new gene-speciﬁc
therapeutic strategies.
This study also examined whether the aberrant splicing effect
produced by the synonymous mutation c.1122CNT in IDS exon 8 could
be neutralized via the use of speciﬁc antisense oligonucleotides. In
patient cells, assays were performed with different AMOs and an LNA
designed to bind to different sites around the new donor splice site.
However, the abnormal transcript was still produced, and a new tran-
script skipping exon 8 was induced. This total absence of exon 8 led to
the in-frame loss of 58 amino acids instead of the 20 lost through the ab-
sence of the last 60 nucleotides of exon 8. In addition, the skipping of
Fig. 5.Hypothetical model for the regulation of the constitutive splicing mechanism around the 3′ splice site of IDS exon 3. Exon 3 contains an exonic splicing silencer (ESS) motif recog-
nized by hnRNP E1 that overlapswith an exonic splicing enhancer (ESE) element bound by SRSF2 (formerly SC35). Both the ESE and ESSmotifs are eliminated by the c.257CNTmutation.
SRSF2 overexpression can rescue the use of the 3′ splice site while hnRNP E1 overexpression increases the use of the downstream cryptic splice site.
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causing in one patient [62]. Thus, the induction of this transcript
would be of no therapeutic use.
Although the tested AOs fulﬁlled most of the criteria for efﬁcacy,
none of them directed exon 8 splicing towards correction. This shows
that even though an AO strategy may be appropriately designed, there
is no guarantee of success. Negative results have been obtained for
50% (17 of 34) of the AOs designed to inhibit ICAM-1 expression [63],
and 33% (52 of 156) of a series of exon-internal AOs designed to induce
exon skipping in the dystrophin gene [64] failed to have the desired ef-
fect. Problems of target accessibility caused by the secondary or tertiary
mRNA structure, and/or by proteins bound to it, might account for some
failures of oligonucleotides [65]. Further, short LNA oligonucleotides
(16-mer or even 12-mer) are known to be more speciﬁc and effective.
The size of the LNA used (20-mer) in the present work, might, therefore
explain (at least partly) its lack of effectiveness. It was not possible to
use a shorter oligonucleotide to speciﬁcally block the region of the
new “gt” donor splice site due to the lack of gene speciﬁcity of b20-
mer sequences; this would certainly derail any attempt at therapy.
It might be thought that the different oligonucleotides obstruct the
access of speciﬁc SR proteins to their respective ESE binding motifs,
thus promoting the skipping of exon 8 [66]. Such a scenario is also pre-
dicted by the in silico analysis results (summarized in Table 2),which in-
dicate exon 8 to contain a region where AO binding occurs, in which
distinct bindingmotifs are likely present at different positions. This pre-
diction is supported by the results of the AMOs and LNA transfection in
control ﬁbroblasts wherein the splicing pattern is changed towards to
aberrant forms (including exon 8 skipping), pointing to an important
role of the predicted exonic bindingmotifs in the 5′ splice site regulation
of exon 8. In addition, since two of the alternative IDS transcripts lack
exon 8 (www.ensembl.org), regulation around this exon may be rather
complex, compromising the efﬁcacy of the AOs assayed. Studies are re-
quired to explore the use of oligonucleotides designed to bind to other
regions of exon 8; an oligonucleotide distant from the mutation might
have a positive effect on the retention of exon 8, helping more effective
solutions for exon 8 recovery to be designed. Until then we should be
careful in consider deﬁnitively that an antisense therapeutic strategyTable 2
In silico prediction of the effect of exonic splicing enhancer (ESE) binding motifs on the
IDS exon 8 mutant sequence (c.1122CNT) using ESRsearch (http://ibis.tau.ac.il/ssat/
ESR.htm) [69], RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) [70] and
ESEﬁnder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/eseﬁnder.cgi?process=home)
[36,37] software. Each column shows the ESE binding motifs present in the mutant exon
8 region where antisense oligonucleotides (AOs) binding occurs. Number of base pairs
of exon 8=174 bp. The AObinding region lies between nucleotides 97 and 134. Numbers
in brackets refer to the ﬁrst nucleotide position of the predicted binding motif.
IDS exon 8
sequence




TGAGAAGCTT (116) TGAGAA (116)
TGAGAAGC (116) GAGAAG (117) GGCAGGT (110)
GAGAAG (117) AGAAGC (118)
TACCTC (132)is not applicable to the splicing rescue of this mutation. Nevertheless,
and as is highlighted by the present study, one such approach may be
particularly challenging for this region of the IDS gene.
Since antisense therapy is mutation-targeted, and the target defects
usually involve ‘private’mutations (i.e., they affect only one person and
his or her family members), it can be understood as personalized
medicine. Efforts are currently underway to allow AOs to be regarded
as a single drug class; this could dramatically accelerate progress in
the development of antisense drug therapies for RNA mis-splicing
diseases [67,68].
To our knowledge this is the ﬁrst attempt to modulate an MPS II-
causing splicing mutation using antisense oligonucleotides. Although
little success was enjoyed, the results raise new questions regarding
the use of antisense therapy in diseases involving ﬁnely regulated
gene systems.
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